Molecular mechanism of β-arrestin-biased agonism at seven-transmembrane receptors

Annual Review of Pharmacology and Toxicology

Volumn 52, Issue , 2012, Pages 179-197

  Reiter, Eric ^a,b,c,d   Ahn, Seungkirl ^e   Shukla, Arun K ^e   Lefkowitz, Robert J ^e  

^a UMR85 PHYSIOLOGIE DE LA REPRODUCTION ET DES COMPORTEMENTS   (France)

^b CNRS   (France)

^c UNIVERSITÉ DE TOURS   (France)

^d Institut Francais du Cheval et de l'Equitation   (France)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Drug discovery; Efficacy; GRKs; Pharmacological bias

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR; BETA ARRESTIN; CARVEDILOL; G PROTEIN COUPLED RECEPTOR; LIGAND;

ARTICLE; BINDING AFFINITY; CELL FUNCTION; CONCEPTUAL FRAMEWORK; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; CRYSTALLOGRAPHY; FLUORESCENCE SPECTROSCOPY; HUMAN; INTRACELLULAR SIGNALING; LIGAND BINDING; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ANIMALS; ARRESTINS; DRUG DISCOVERY; HUMANS; LIGANDS; MODELS, MOLECULAR; PHOSPHORYLATION; PROTEIN CONFORMATION; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION;

EID: 84855901533     PISSN: 03621642     EISSN: 15454304     Source Type: Book Series    
DOI: 10.1146/annurev.pharmtox.010909.105800     Document Type: Article

References (90)

1. Lagerstr̈om MC, Schïoth HB. 2008. Structural diversity of G protein-coupled receptors and significance for drug discovery. Nat. Rev. Drug Discov. 7:339-57
2. Ma P, Zemmel R. 2002. Value of novelty? Nat. Rev. Drug Discov. 1:571-72
3. LuttrellLM. 2006. Transmembrane signaling byGprotein-coupled receptors. MethodsMol. Biol. 332:3-49
4. Jean-Alphonse F, Hanyaloglu AC. 2011. Regulation of GPCR signal networks via membrane trafficking. Mol. Cell. Endocrinol. 331:205-14
5. Hermans E. 2003. Biochemical and pharmacological control of the multiplicity of coupling at G-proteincoupled receptors. Pharmacol. Ther. 99:25-44 (Pubitemid 36694748)
6. Lefkowitz RJ, Pierce KL, Luttrell LM. 2002. Dancing with different partners: protein kinase A phosphorylation of seven membrane-spanning receptors regulates their G protein-coupling specificity. Mol. Pharmacol. 62:971-74 (Pubitemid 35222487)
7. Bockaert J, Dumuis A, Fagni L,Marin P. 2004. GPCR-GIP networks: a first step in the discovery of new therapeutic drugs? Curr. Opin. Drug Discov. Dev. 7:649-57 (Pubitemid 39329867)
8. Lefkowitz RJ, Shenoy SK. 2005. Transduction of receptor signals by β-arrestins. Science 308:512-17
9. Lefkowitz RJ. 1998. G protein-coupled receptors: III. New roles for receptor kinases and β-arrestins in receptor signaling and desensitization. J. Biol. Chem. 273:18677-80 (Pubitemid 28366245)
10. Reiter E, Lefkowitz RJ. 2006. GRKs and β-arrestins: roles in receptor silencing, trafficking and signaling. Trends Endocrinol. Metab. 17:159-65
11. Penela P, Murga C, Ribas C, Lafarga V, Mayor F Jr. 2010. The complex G protein-coupled receptor kinase 2 (GRK2) interactome unveils new physiopathological targets. Br. J. Pharmacol. 160:821-32
12. Xiao K, McClatchy DB, Shukla AK, Zhao Y, Chen M, et al. 2007. Functional specialization of β-arrestin interactions revealed by proteomic analysis. Proc. Natl. Acad. Sci. USA 104:12011-16 (Pubitemid 47185621)
13. Xiao K, Sun J, Kim J, Rajagopal S, Zhai B, et al. 2010. Global phosphorylation analysis of β-arrestinmediated signaling downstream of a seven transmembrane receptor (7TMR). Proc. Natl. Acad. Sci. USA 107:15299-304
14. Barnes WG, Reiter E, Violin JD, Ren XR, Milligan G, Lefkowitz RJ. 2005. β-Arrestin 1 and Galphaq/11 coordinately activate RhoA and stress fiber formation following receptor stimulation. J. Biol. Chem. 280:8041-50 (Pubitemid 40349702)
15. Gao H, Sun Y, Wu Y, Luan B,Wang Y, et al. 2004. Identification of β-arrestin2 as a G protein-coupled receptor-stimulated regulator of NF-κB pathways. Mol. Cell 14:303-17 (Pubitemid 38591402)
16. Witherow DS, Garrison TR, Miller WE, Lefkowitz RJ. 2004. β-Arrestin inhibits NF-κB activity by means of its interaction with the NF-κB inhibitor IκBα. Proc. Natl. Acad. Sci. USA 101:8603-7 (Pubitemid 38745817)
17. Beaulieu JM, Sotnikova TD, Marion S, Lefkowitz RJ, Gainetdinov RR, Caron MG. 2005. An Akt/β-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell 122:261-73 (Pubitemid 41032989)
18. DeWire SM, Kim J, Whalen EJ, Ahn S, Chen M, Lefkowitz RJ. 2008. β-arrestin-mediated signaling regulates protein synthesis. J. Biol. Chem. 283:10611-20
19. Ahn S, Kim J, Hara MR, Ren XR, Lefkowitz RJ. 2009. β-Arrestin-2 mediates anti-apoptotic signaling through regulation of BAD phosphorylation. J. Biol. Chem. 284:8855-65
20. Walters RW, Shukla AK, Kovacs JJ, Violin JD, DeWire SM, et al. 2009. β-Arrestin1 mediates nicotinic acid-induced flushing, but not its antilipolytic effect, in mice. J. Clin. Investig. 119:1312-21
21. Kovacs JJ, Whalen EJ, Liu R, Xiao K, Kim J, et al. 2008. β-arrestin-mediated localization of Smoothened to the primary cilium. Science 320:1777-81 (Pubitemid 351931292)
22. Stephenson RP. 1956. A modification of receptor theory. Br. J. Pharmacol. Chemother. 11:379-93
23. Samama P, Cotecchia S, Costa T, Lefkowitz RJ. 1993. A mutation-induced activated state of the β2-adrenergic receptor: extending the ternary complex model. J. Biol. Chem. 268:4625-36 (Pubitemid 23081571)
24. Kenakin T. 2005. New concepts in drug discovery: collateral efficacy and permissive antagonism. Nat. Rev. Drug Discov. 4:919-27 (Pubitemid 41637694)
25. Galandrin S, Oligny-Longpre G, Bouvier M. 2007. The evasive nature of drug efficacy: implications for drug discovery. Trends Pharmacol. Sci. 28:423-30 (Pubitemid 47087968)
26. Violin JD, Lefkowitz RJ. 2007.β-arrestin-biased ligands at seven-transmembrane receptors. Trends Pharmacol. Sci. 28:416-22
27. Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka B, et al. 2007. Functional selectivity and classical concepts of quantitative pharmacology. J. Pharmacol. Exp. Ther. 320:1-13 (Pubitemid 46025713)
28. Christopoulos A, Christopoulos G, Morfis M, Udawela M, Laburthe M, et al. 2003. Novel receptor partners and function of receptor activity-modifying proteins. J. Biol. Chem. 278:3293-97 (Pubitemid 36801242)
29. Kenakin T. 2002. Efficacy at G-protein-coupled receptors. Nat. Rev. Drug Discov. 1:103-10 (Pubitemid 41646517)
30. Wei H, Ahn S, Shenoy SK, Karnik SS, Hunyady L, et al. 2003. Independent β-arrestin 2 and G proteinmediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2. Proc. Natl. Acad. Sci. USA 100:10782-87 (Pubitemid 37140105)
31. Gesty-Palmer D, Chen M, Reiter E, Ahn S, Nelson CD, et al. 2006. Distinct β-arrestin-and G proteindependent pathways for parathyroid hormone receptor-stimulated ERK1/2 activation. J. Biol. Chem. 281:10856-64 (Pubitemid 43855508)
32. Azzi M, Charest PG, Angers S, Rousseau G, Kohout T, et al. 2003. β-arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors. Proc. Natl. Acad. Sci. USA 100:11406-11 (Pubitemid 37205948)
33. Kenakin T. 2007. Collateral efficacy in drug discovery: taking advantage of the good (allosteric) nature of 7TM receptors. Trends Pharmacol. Sci. 28:407-15 (Pubitemid 47087972)
34. Kenakin T. 2003. Ligand-selective receptor conformations revisited: the promise and the problem. Trends Pharmacol. Sci. 24:346-54 (Pubitemid 37315526)
35. Rajagopal S, Rajagopal K, Lefkowitz RJ. 2010. Teaching old receptors new tricks: biasing seventransmembrane receptors. Nat. Rev. Drug Discov. 9:373-86
36. Rajagopal S, Ahn S, Rominger DH, Gowen-McDonald W, Lam CM, et al. 2011. Quantifying ligand bias at seven-transmembrane receptors. Mol. Pharmacol. 80:367-77
37. Black JW, Leff P. 1983. Operational models of pharmacological agonism. Proc. R. Soc. Lond. Ser. B 220:141-62 (Pubitemid 14217337)
38. Swaminath G, Deupi X, Lee TW, Zhu W, Thian FS, et al. 2005. Probing the β2 adrenoceptor binding site with catechol reveals differences in binding and activation by agonists and partial agonists. J. Biol. Chem. 280:22165-71 (Pubitemid 40827872)
39. Yao X, Parnot C, Deupi X, Ratnala VR, Swaminath G, et al. 2006. Coupling ligand structure to specific conformational switches in the β2- adrenoceptor. Nat. Chem. Biol. 2:417-22 (Pubitemid 44114919)
40. Schwartz TW, Frimurer TM,Holst B, Rosenkilde MM, Elling CE. 2006. Molecular mechanism of 7TM receptor activation-a global toggle switch model. Annu. Rev. Pharmacol. Toxicol. 46:481-519 (Pubitemid 43271198)
41. Georgieva T, Devanathan S, StropovaD,Park CK, Salamon Z, et al. 2008. Unique agonist-bound cannabinoid CB1 receptor conformations indicate agonist specificity in signaling. Eur. J. Pharmacol. 581:19-29
42. Granier S, Kim S, Shafer AM, Ratnala VR, Fung JJ, et al. 2007. Structure and conformational changes in the C-terminal domain of the β2-adrenoceptor: insights from fluorescence resonance energy transfer studies. J. Biol. Chem. 282:13895-905 (Pubitemid 47100565)
43. Reiner S, Ambrosio M, Hoffmann C, Lohse MJ. 2010. Differential signaling of the endogenous agonists at the β2-adrenergic receptor. J. Biol. Chem. 285:36188-98
44. Zurn A, Zabel U, Vilardaga JP, Schindelin H, Lohse MJ, Hoffmann C. 2009. Fluorescence resonance energy transfer analysis ofα2a-adrenergic receptor activation reveals distinct agonist-specific conformational changes. Mol. Pharmacol. 75:534-41
45. Hoffmann C, Zurn A, Bunemann M, Lohse MJ. 2008. Conformational changes in G-protein-coupled receptors-the quest for functionally selective conformations is open. Br. J. Pharmacol. 153(Suppl. 1):S358-66
46. ZieglerN, Batz J, Zabel U, Lohse MJ,Hoffmann C. 2010. FRET-based sensors for the humanM1-,M3-, and M5-acetylcholine receptors. Bioorg. Med. Chem. 19:1048-54
47. Kahsai AW, Xiao K, Rajagopal S, Ahn S, Shukla AK, et al. 2011. Multiple ligand-specific conformations of the β2-adrenergic receptor. Nat. Chem. Biol. 7:692-700
48. Rosenkilde MM, Benned-Jensen T, Frimurer TM, Schwartz TW. 2010. The minor binding pocket: a major player in 7TM receptor activation. Trends Pharmacol. Sci. 31:567-74
49. Rasmussen SG, Choi HJ, Fung JJ, Pardon E, Casarosa P, et al. 2011. Structure of a nanobody-stabilized active state of the β2 adrenoceptor. Nature 469:175-80
50. Rosenbaum DM, Zhang C, Lyons JA, Holl R, Aragao D, et al. 2011. Structure and function of an irreversible agonist-β2 adrenoceptor complex. Nature 469:236-40
51. Cherezov V, RosenbaumDM, Hanson MA, Rasmussen SG, Thian FS, et al. 2007. High-resolution crystal structure of an engineered human β2-adrenergic G protein-coupled receptor. Science 318:1258-65 (Pubitemid 350172884)
52. Rosenbaum DM, Cherezov V, Hanson MA, Rasmussen SG, Thian FS, et al. 2007. GPCR engineering yields high-resolution structural insights into β2-adrenergic receptor function. Science 318:1266-73 (Pubitemid 350172885)
53. Rasmussen SG, Choi HJ, Rosenbaum DM, Kobilka TS, Thian FS, et al. 2007. Crystal structure of the human β2 adrenergic G-protein-coupled receptor. Nature 450:383-87 (Pubitemid 350126755)
54. Warne T, Moukhametzianov R, Baker JG, Nehme R, Edwards PC, et al. 2011. The structural basis for agonist and partial agonist action on a β1-adrenergic receptor. Nature 469:241-44
55. Warne T, Serrano-Vega MJ, Baker JG, Moukhametzianov R, Edwards PC, et al. 2008. Structure of a β1-adrenergic G-protein-coupled receptor. Nature 454:486-91
56. Jaakola VP, Griffith MT, Hanson MA, Cherezov V, Chien EY, et al. 2008. The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist. Science 322:1211-17
57. Bokoch MP, Zou Y, Rasmussen SG, Liu CW, Nygaard R, et al. 2010. Ligand-specific regulation of the extracellular surface of a G-protein-coupled receptor. Nature 463:108-12
58. May LT, Leach K, Sexton PM, Christopoulos A. 2007. Allosteric modulation of G protein-coupled receptors. Annu. Rev. Pharmacol. Toxicol. 47:1-51 (Pubitemid 46277033)
59. Dias JA, Bonnet B,Weaver BA,Watts J, KluetzmanK, et al. 2011. A negative allosteric modulator demonstrates biased antagonism of the follicle stimulating hormone receptor. Mol. Cell. Endocrinol. 333:143-50
60. Kobilka BK, Deupi X. 2007. Conformational complexity of G-protein-coupled receptors. Trends Pharmacol. Sci. 28(8): 397-406 (Pubitemid 47087966)
61. Vaidehi N. 2010. Dynamics and flexibility of G-protein-coupled receptor conformations and their relevance to drug design. Drug Discov. Today. 15(21-22):951-57
62. Dror RO, Arlow DH, Borhani DW, Jensen MO, Piana S, Shaw DE. 2009. Identification of two distinct inactive conformations of the β2-adrenergic receptor reconciles structural and biochemical observations. Proc. Natl. Acad. Sci. USA 106:4689-94
63. Whalen EJ, Rajagopal S, Lefkowitz RJ. 2011. Therapeutic potential of β-arrestin-and G protein-biased agonists. Trends Mol. Med. 17(3):126-39
64. Violin JD, DeWire SM, Yamashita D, Rominger DH, Nguyen L, et al. 2010. Selectively engaging β-arrestins at the angiotensin II type 1 receptor reduces blood pressure and increases cardiac performance. J. Pharmacol. Exp. Ther. 335:572-79
65. Xiao K, Shenoy SK, Nobles K, Lefkowitz RJ. 2004. Activation-dependent conformational changes in β-arrestin 2. J. Biol. Chem. 279:55744-53
66. Nobles KN, Guan Z, Xiao K, Oas TG, Lefkowitz RJ. 2007. The active conformation of β-arrestin1: direct evidence for the phosphate sensor in the N-domain and conformational differences in the active states of β-arrestins1 and-2. J. Biol. Chem. 282:21370-81 (Pubitemid 47099966)
67. Charest PG, Terrillon S, Bouvier M. 2005. Monitoring agonist-promoted conformational changes of β-arrestin in living cells by intramolecular BRET. EMBO Rep. 6:334-40 (Pubitemid 40561625)
68. Shukla AK, Violin JD, Whalen EJ, Gesty-Palmer D, Shenoy SK, Lefkowitz RJ. 2008. Distinct conformational changes in β-arrestin report biased agonism at seven-transmembrane receptors. Proc. Natl. Acad. Sci. USA 105:9988-93
69. Gurevich VV, Benovic JL. 1993. Visual arrestin interaction with rhodopsin: Sequential multisite binding ensures strict selectivity toward light-activated phosphorylated rhodopsin. J. Biol. Chem. 268:11628-38 (Pubitemid 23168111)
70. Kim J, Ahn S, Ren XR, Whalen EJ, Reiter E, et al. 2005. Functional antagonism of different G proteincoupled receptor kinases for β-arrestin-mediated angiotensin II receptor signaling. Proc. Natl. Acad. Sci. USA 102:1442-47 (Pubitemid 40209189)
71. Ren XR, Reiter E, Ahn S, Kim J, Chen W, Lefkowitz RJ. 2005. Different G protein-coupled receptor kinases govern G protein and β-arrestin-mediated signaling of V2 vasopressin receptor. Proc. Natl. Acad. Sci. USA 102:1448-53 (Pubitemid 40209190)
72. Shenoy SK, Drake MT, Nelson CD, Houtz DA, Xiao K, et al. 2006. β-Arrestin-dependent, G proteinindependent ERK1/2 activation by the β2 adrenergic receptor. J. Biol. Chem. 281:1261-73
73. Kara E, Crepieux P, Gauthier C, Martinat N, Piketty V, et al. 2006. A phosphorylation cluster of five serine and threonine residues in the C-terminus of the follicle-stimulating hormone receptor is important for desensitization but not for β-arrestin-mediated ERK activation. Mol. Endocrinol. 20:3014-26 (Pubitemid 44833552)
74. Iwata K, Luo J, Penn RB, Benovic JL. 2005. Bimodal regulation of the human H1 histamine receptor by G protein-coupled receptor kinase 2. J. Biol. Chem. 280:2197-204
75. Zidar DA, Violin JD, WhalenEJ, LefkowitzRJ. 2009. Selective engagement ofGprotein coupled receptor kinases (GRKs) encodes distinct functions of biased ligands. Proc. Natl. Acad. Sci. USA 106:9649-54
76. Oakley RH, Laporte SA, Holt JA, Barak LS, Caron MG. 2001. Molecular determinants underlying the formation of stable intracellular G protein-coupled receptor-β-arrestin complexes after receptor endocytosis. J. Biol. Chem. 276:19452-60
77. Oakley RH, Laporte SA, Holt JA, Caron MG, Barak LS. 2000. Differential affinities of visual arrestin, βarrestin1, and βarrestin2 for G protein-coupled receptors delineate two major classes of receptors. J. Biol. Chem. 275:17201-10 (Pubitemid 30398969)
78. Busillo JM, Armando S, Sengupta R, Meucci O, Bouvier M, Benovic JL. 2010. Site-specific phosphorylation of CXCR4 is dynamically regulated by multiple kinases and results in differential modulation of CXCR4 signaling. J. Biol. Chem. 285:7805-17
79. Butcher AJ, Prihandoko R, Kong KC, McWilliams P, Edwards JM, et al. 2011. Differential G-protein coupled receptor phosphorylation provides evidence for a signalling barcode. J. Biol. Chem. 286:11506-18
80. Nobles KN, Xiao K, Ahn S, Shukla AK, Lam CM, et al. 2011. Distinct phosphorylation sites on the β2-adrenergic receptor establish a barcode that encodes differential functions of β-arrestin. Sci. Signal. 4:ra51
81. Wisler JW,DeWire SM, Whalen EJ, Violin JD, DrakeMT, et al. 2007. A unique mechanism ofβ-blocker action: carvedilol stimulates β-arrestin signaling. Proc. Natl. Acad. Sci. USA 104:16657-62 (Pubitemid 350211072)
82. Heitzler D, Durand G, Rizk A, Ahn S, Kim J, et al. 2011. GRKs: molecular switches controlling the balance between G protein and β-arrestin-mediated signaling by 7TMRs. Submitted
83. 2C receptor C-terminus is essential for G protein-independent, arrestin-dependent receptor signaling. Mol. Biol. Cell 19:4640-50
84. Kim IM, Tilley DG, Chen J, Salazar NC, Whalen EJ, et al. 2008. β-Blockers alprenolol and carvedilol stimulate β-arrestin-mediated EGFR transactivation. Proc. Natl. Acad. Sci. USA 105:14555-60
85. Noma T, Lemaire A, Naga Prasad SV, Barki-Harrington L, Tilley DG, et al. 2007. β-arrestin-mediated β1-adrenergic receptor transactivation of the EGFR confers cardioprotection. J. Clin. Investig. 117:2445-58
86. Bristow MR. 2000. β-Adrenergic receptor blockade in chronic heart failure. Circulation 101:558-69 (Pubitemid 30080872)
87. Lohse MJ, Engelhardt S, Eschenhagen T. 2003. What is the role of β-adrenergic signaling in heart failure? Circ. Res. 93:896-906 (Pubitemid 37433227)
88. Gesty-Palmer D, Flannery P, Yuan L, Corsino L, SpurneyR, et al. 2009. Aβ-arrestin-biased agonist of the parathyroid hormone receptor (PTH1R) promotes bone formation independent of G protein activation. Sci. Transl. Med. 1:1ra1
89. Bodor ET, Offermanns S. 2008. Nicotinic acid: an old drug with a promising future. Br. J. Pharmacol. 153(Suppl. 1):S68-75 (Pubitemid 351340990)
90. Semple G, Skinner PJ, Gharbaoui T, Shin YJ, Jung JK, et al. 2008. 3-(1H-tetrazol-5-yl)-1,4,5,6-tetrahydro-cyclopentapyrazole (MK-0354): a partial agonist of the nicotinic acid receptor, G-protein coupled receptor 109a, with antilipolytic but no vasodilatory activity in mice. J. Med. Chem. 51:5101-8